ArticleBMJ (Clinical research ed.)2022

Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.

Niklas Worm Andersson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.